Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ProQR Therapeutics N.V. (PRQR)

2.89   0.04 (1.4%) 01-27 16:00
Open: 2.82 Pre. Close: 2.85
High: 2.97 Low: 2.785
Volume: 1,008,438 Market Cap: 206(M)

Technical analysis

as of: 2023-01-27 4:47:14 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.41     One year: 5.15
Support: Support1: 2.41    Support2: 1.56
Resistance: Resistance1: 3.77    Resistance2: 4.41
Pivot: 3.13
Moving Average: MA(5): 2.78     MA(20): 3.21
MA(100): 1.54     MA(250): 1.23
MACD: MACD(12,26): 0.1     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 31.5     %D(3): 27.5
RSI: RSI(14): 52.1
52-week: High: 6.15  Low: 0.52
Average Vol(K): 3-Month: 3,080 (K)  10-Days: 1,764 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PRQR ] has closed above bottom band by 32.5%. Bollinger Bands are 107% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.97 - 2.99 2.99 - 3
Low: 2.76 - 2.77 2.77 - 2.78
Close: 2.87 - 2.89 2.89 - 2.91

Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Headline News

Sun, 29 Jan 2023
ProQR Therapeutics (NASDAQ:PRQR) Receives Average ... - MarketBeat

Fri, 27 Jan 2023
ProQR Therapeutics N.V. (NASDAQ:PRQR) Up Almost 5.17% In 1 ... - Marketing Sentinel

Thu, 26 Jan 2023
Can ProQR Therapeutics NV (PRQR) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver

Thu, 19 Jan 2023
Institutions along with individual investors who hold considerable shares inProQR Therapeutics N.V. (NASDAQ:PRQR) come under pressure; lose 11% of holdings value - Simply Wall St

Wed, 18 Jan 2023
LLY: 4 Pharma Stocks You Shouldn't Think Twice About Buying in ... -

Wed, 11 Jan 2023
ProQR Therapeutics (NASDAQ:PRQR) Lifted to "Hold" at StockNews ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 71 (M)
% Held by Insiders 5.721e+007 (%)
% Held by Institutions 20.8 (%)
Shares Short 686 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.6e+007
EPS Est Next Qtl -0.52
EPS Est This Year -2.11
EPS Est Next Year -1.75
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 694.6
Return on Equity (ttm) -26.3
Qtrly Rev. Growth 3.93e+006
Gross Profit (p.s.) -50.46
Sales Per Share -338.69
EBITDA (p.s.) 1.09091e+007
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -47 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.69

Stock Dividends

Dividend 0
Forward Dividend 990150
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.